Guangzhou Baiyunshan Pharmaceutical Holdings Dividende
Zukünftiges Wachstum Kriterienprüfungen 4/6
Guangzhou Baiyunshan Pharmaceutical Holdings ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 3.8%, die durch die Erträge gut gedeckt ist.
Wichtige Informationen
4.0%
Dividendenausschüttung
30%
Ausschüttungsquote
| Durchschnittlicher Branchenertrag | 4.2% |
| Nächster Dividendenzahlungstermin | n/a |
| Ex-Dividendendatum | n/a |
| Dividende pro Aktie | HK$0.814 |
| Gewinn pro Aktie | HK$2.53 |
| Erwartete Dividendenrendite in 3 Jahren | 4.7% |
Aktuelle Dividendenentwicklung
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Recent updates
A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: 874Die Dividendenzahlungen des Unternehmens waren in den vergangenen 10 Jahren volatil.
Wachsende Dividende: 874 Die Dividendenzahlungen des Unternehmens sind in den letzten 10 Jahren gestiegen.
Dividendenrendite im Vergleich zum Markt
| Guangzhou Baiyunshan Pharmaceutical Holdings Dividendenrendite im Vergleich zum Markt |
|---|
| Segment | Dividendenrendite |
|---|---|
| Unternehmen (874) | 4.0% |
| Untere 25 % des Marktes (HK) | 3.4% |
| Markt Top 25 % (HK) | 8.1% |
| Branchendurchschnitt (Healthcare) | 4.2% |
| Analystenprognose in 3 Jahren (874) | 4.7% |
Bemerkenswerte Dividende: 874Die Dividende des Unternehmens (3.61%) ist höher als die der untersten 25 % der Dividendenzahler auf dem Markt Hong Kong (3.12%).
Hohe Dividende: 874Die Dividende des Unternehmens (3.61%) ist im Vergleich zu den besten 25 % der Dividendenzahler auf dem Markt Hong Kong (7.56%) niedrig.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Mit einer relativ niedrigen Ausschüttungsquote (29.7%) sind die Dividendenzahlungen von 874 gut durch die Erträge gedeckt.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Mit einer angemessenen Ausschüttungsquote (58.2%) sind die Dividendenzahlungen von 874 durch den Cashflow gedeckt.